ERBB2 and neoplasm: Five different antibody moieties directed against four distinct tumor-associated antigens were employed, including the EGFR-targeting antibody hu225 derived from antibody C225 used in cetuximab [29] and humanized by CDR grafting [30], the trastuzumab-derived 4D5 directed against HER2 [31], the HER3-targeting antibodies 3M6 (a modified version of MM-121, Ab#6 [32] with a mutation of C89 of the VL according to the Kabat numbering scheme to serine) and 3-43 [33], as well as the humanized version 323/A3hu3 [34] of the anti-EpCAM antibody 323/A3 [35, 36].